NCT00935792View on ClinicalTrials.gov

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Lymphocytic Leukemia
Interventions
DRUG

alemtuzumab

Given subcutaneously

DRUG

everolimus

Given orally

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER